MA52626A - Anticorps anti-cd63, conjugués et leurs utilisations - Google Patents

Anticorps anti-cd63, conjugués et leurs utilisations

Info

Publication number
MA52626A
MA52626A MA052626A MA52626A MA52626A MA 52626 A MA52626 A MA 52626A MA 052626 A MA052626 A MA 052626A MA 52626 A MA52626 A MA 52626A MA 52626 A MA52626 A MA 52626A
Authority
MA
Morocco
Prior art keywords
conjugates
antibodies
Prior art date
Application number
MA052626A
Other languages
English (en)
Inventor
Andrew Baik
Katherine Cygnar
Andrew J Murphy
Christopher Schoenherr
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66691071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA52626(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA52626A publication Critical patent/MA52626A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2428—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA052626A 2018-05-17 2019-05-17 Anticorps anti-cd63, conjugués et leurs utilisations MA52626A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862673098P 2018-05-17 2018-05-17
US201862681563P 2018-06-06 2018-06-06
US201862777592P 2018-12-10 2018-12-10

Publications (1)

Publication Number Publication Date
MA52626A true MA52626A (fr) 2021-03-24

Family

ID=66691071

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052626A MA52626A (fr) 2018-05-17 2019-05-17 Anticorps anti-cd63, conjugués et leurs utilisations

Country Status (16)

Country Link
US (2) US12252544B2 (fr)
EP (1) EP3793591A1 (fr)
JP (1) JP7477462B2 (fr)
KR (2) KR20250140631A (fr)
CN (1) CN112135624B (fr)
AU (2) AU2019269685B2 (fr)
BR (1) BR112020023145A2 (fr)
CA (2) CA3290882A1 (fr)
CL (3) CL2020002965A1 (fr)
CO (1) CO2020015052A2 (fr)
MA (1) MA52626A (fr)
MX (2) MX2020012350A (fr)
MY (1) MY206284A (fr)
PH (1) PH12020551955A1 (fr)
SG (1) SG11202011232VA (fr)
WO (1) WO2019222663A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018281280B2 (en) 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
EP3793591A1 (fr) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anticorps anti-cd63, conjugués et leurs utilisations
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US20250277052A1 (en) * 2021-03-29 2025-09-04 Immunewalk Therapeutics, Inc. Motile sperm domain containing protein 2, integrin beta2 and cd63
IL314482A (en) 2022-02-02 2024-09-01 Regeneron Pharma Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
WO2023194501A1 (fr) * 2022-04-05 2023-10-12 Altheia Science S.R.L. Traitement de troubles myéloïdes et de leucémies aiguës ciblant de nouveaux antigènes spécifiques à une tumeur
CN116041520B (zh) * 2022-12-28 2023-09-22 武汉爱博泰克生物科技有限公司 针对Human CD63的兔单克隆抗体及其制备方法和应用
IL326018A (en) 2023-07-28 2026-03-01 Regeneron Pharma Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease
AU2024315073A1 (en) 2023-07-28 2026-01-22 Regeneron Pharmaceuticals, Inc. Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
WO2025149667A1 (fr) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Conjugués anticorps-médicament et leurs utilisations
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025184567A1 (fr) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Procédés et compositions pour redosage d'un aav à l'aide d'un anticorps antagoniste anti-cd40 pour supprimer une réponse d'anticorps anti-aav hôte

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US5229272A (en) 1989-04-25 1993-07-20 Igen, Inc. Catalytic antibody components
US5156965A (en) 1983-11-29 1992-10-20 Igen, Inc. Catalytic antibodies
US5030717A (en) 1986-09-17 1991-07-09 Scripps Clinic And Research Foundation Antibodies which catalyze hydrolysis of ester bonds
US5126258A (en) 1984-09-07 1992-06-30 Scripps Clinic And Research Foundation Molecules with antibody combining sites that exhibit catalytic properties
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5851527A (en) 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
CA2161114A1 (fr) 1993-04-23 1994-11-10 Andrew D. Napper Anticorps catalytiques hydrolysant des amides primaires; methodes d'elicitation de ces anticorps
US5602021A (en) 1994-12-29 1997-02-11 Catalytic Antibodies, Inc. Method for generating proteolytic enzymes specific against a selected peptide sequence
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6261554B1 (en) 1995-07-25 2001-07-17 Introgene B.V. Compositions for targeted gene delivery
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
US5962313A (en) 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
ES2191827T3 (es) 1996-10-17 2003-09-16 Immunomedics Inc Conjugado de toxina no antigenica y proteina de fusion de un sistema receptor de penetracion intracelular.
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP2002511857A (ja) 1997-06-11 2002-04-16 ザ スクール オブ ファーマシー ユニヴァーシティ オブ ロンドン 抗体−酵素複合体をプロドラッグと組合せて含む薬学的組成物
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
ES2322975T3 (es) 1998-01-15 2009-07-02 Center For Molecular Medicine And Immunology Componente direccionador biespecifico que comprende un anticuerpo contra el antigeno carcinoembrionario (cea) y la region de union a ligando de la subunidad alfa del receptor de il-13.
US6703488B1 (en) 1998-01-15 2004-03-09 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
US6235714B1 (en) 1998-03-23 2001-05-22 Sudhir Paul Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
US6855804B2 (en) 1998-03-23 2005-02-15 Board Of Regents, The University Of Texas System Covalently reactive transition state analogs and methods of use thereof
DK1068238T3 (da) 1998-04-02 2013-01-14 Xintela Ab Integrinheterodimer og subunit deraf
DE69941187D1 (de) 1998-06-01 2009-09-10 Agensys Inc Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7223556B1 (en) 1998-10-09 2007-05-29 President And Fellows Of Harvard College Targeted proteolysis by recruitment to ubiquitin protein ligases
JP2003523178A (ja) 1999-11-15 2003-08-05 ユニバーシティ・オブ・サザン・カリフォルニア 治療又は診断のための成分の攻撃目標を設定したデリバリー
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
DE10034607A1 (de) 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
AU2001295041A1 (en) 2000-09-08 2002-03-22 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US7442777B2 (en) 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7431923B2 (en) 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7534429B2 (en) 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US20060210474A1 (en) 2000-11-29 2006-09-21 Young David S Cytotoxicity mediation of cells evidencing surface expression of CD63
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
JP4381140B2 (ja) 2001-10-12 2009-12-09 シェーリング コーポレイション 免疫応答を調節するための二重特異性抗体の使用
US20050003014A1 (en) 2001-12-21 2005-01-06 Ketelson Howard Allen Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
WO2003057179A2 (fr) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Utilisation de p97 en tant que systeme d'administration d'enzymes en vue d'administrer des enzymes lysosomales therapeutiques
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
WO2004023973A2 (fr) 2002-09-12 2004-03-25 Incyte Corporation Molecules utilisees a des fins diagnostiques et therapeutiques
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
PT1587923E (pt) 2003-01-22 2011-12-07 Univ Duke Construções melhoradas para a expressão de polipéptidos lisossomais
SE0301087D0 (sv) 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
JP4979067B2 (ja) 2003-05-01 2012-07-18 ジェンザイム・コーポレーション 神経代謝性疾患についての遺伝子治療
EP1633865B1 (fr) 2003-06-18 2011-09-28 Bayer Pharma Aktiengesellschaft Nouvelles entités biologiques et leur utilisation
WO2005007695A2 (fr) 2003-07-14 2005-01-27 Beth Israel Deaconess Medical Center, Inc. Anticorps anti-cd63 antibodies et leurs methodes d'utilisation
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US7371539B2 (en) 2003-12-03 2008-05-13 President And Fellows Of Harvard College Targeted polypeptide degradation
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US20080014188A1 (en) 2004-02-06 2008-01-17 Zankel Todd C Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof
WO2005077333A2 (fr) 2004-02-10 2005-08-25 University Of Florida Research Foundation, Inc. Administration sous forme de gel de vecteurs de virus associes aux adenovirus recombines
DE602005020745D1 (de) 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
CA2556752C (fr) 2004-02-23 2016-02-02 Genentech, Inc. Liants et conjugues heterocycliques auto-immolateurs
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
US20060171926A1 (en) 2004-04-30 2006-08-03 Passini Marco A Gene therapy for neurometabolic disorders
EP1828390B1 (fr) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Vecteurs chimeriques
JP5137814B2 (ja) 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
AU2006243776A1 (en) 2005-05-02 2006-11-09 Genzyme Corporation Gene therapy for neurometabolic disorders
CA2611985C (fr) 2005-06-17 2016-08-16 The University Of North Carolina At Chapel Hill Procedes, systemes et materiaux de fabrication de nanoparticules
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
CN105709237A (zh) 2005-12-16 2016-06-29 Ibc 医药公司 基于免疫球蛋白的多价生物活性装配体
CA2641070C (fr) 2006-02-06 2017-01-03 Ramot At Tel-Aviv University Ltd. Enzymotherapie de remplacement pour le traitement des maladies lysosomiales
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
WO2008014404A2 (fr) 2006-07-26 2008-01-31 The University Of Chicago Administration médiée par des récepteurs: compositions et méthodes
US20080089891A1 (en) 2006-07-26 2008-04-17 Arius Research, Inc. Cancerous disease modifying antibodies
CA2661023C (fr) 2006-08-18 2017-08-15 Novartis Ag Anticorps specifiques du prlr et leurs utilisations
AU2007322123A1 (en) 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
WO2008103993A2 (fr) 2007-02-23 2008-08-28 University Of Florida Research Foundation, Inc. Compositions et procédés pour le traitement de maladies liées au stockage du glycogène
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
WO2008122039A2 (fr) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molécules d'anticorps hybrides médiées par la sélénocystéine
US8569032B2 (en) 2007-05-18 2013-10-29 Tokyo Metropolitan Institute Of Medical Science Proteins having acquired A-galactosidase activity
US7985557B2 (en) 2007-05-23 2011-07-26 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
DK2150617T3 (en) 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
WO2009075815A1 (fr) 2007-12-07 2009-06-18 Duke University Thérapie génique d'immunomodulation
WO2009094561A1 (fr) 2008-01-24 2009-07-30 The Government Of The United States Of America As Represented By The Secretary Of The Departmentof Internalisation induite de récepteurs de surface
US9617548B2 (en) 2008-04-22 2017-04-11 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
WO2009137721A2 (fr) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Peptides de ciblage lysosomial et leurs utilisations
ES2560807T3 (es) 2008-07-21 2016-02-22 Polytherics Limited Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
KR20110047255A (ko) 2008-09-26 2011-05-06 로슈 글리카트 아게 이중특이적 항-ｅｇｆｒ／항-ｉｇｆ-１ｒ 항체
CN102378768A (zh) 2009-04-07 2012-03-14 罗氏格黎卡特股份公司 双特异性抗-ErbB-3/抗-c-Met抗体
EP2241576A1 (fr) 2009-04-17 2010-10-20 Trion Pharma Gmbh Utilisation des anticorps bispécifiques trifonctionnels pour le traitement des tumeurs associées aux cellules souches de cancer CD133+/EpCAM+
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
EA022786B1 (ru) 2009-07-31 2016-03-31 Этрис Гмбх Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
WO2011029823A1 (fr) 2009-09-09 2011-03-17 Novartis Ag Anticorps monoclonal réactif avec cd63 lors de son expression à la surface de mastocytes dégranulés
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
WO2011140279A1 (fr) 2010-05-04 2011-11-10 Wayne State University Ciblage sous-cellulaire faisant intervenir aav de rhodopsines hétérologues dans des cellules ganglionnaires rétiniennes
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
BR112013007616B1 (pt) 2010-09-29 2023-01-24 Oxyrane Uk Limited Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero
US8679478B2 (en) 2010-10-04 2014-03-25 Duke University Methods of lysosomal storage disease therapy
WO2012051220A1 (fr) 2010-10-11 2012-04-19 Wichita State University Système de délivrance de médicaments de nanoparticules magnétiques composites
HRP20181315T1 (hr) 2010-11-22 2018-10-19 Amicus Therapeutics, Inc. Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina
CN105861548B (zh) 2011-02-25 2020-01-10 瑞泽恩制药公司 Adam6小鼠
EP2687597B1 (fr) 2011-03-16 2018-12-26 Amano Enzyme Inc. Alpha-glucosidase modifiée et ses applications
WO2012125987A2 (fr) 2011-03-17 2012-09-20 Massachusetts Institute Of Technology Système d'administration
ES2745470T3 (es) 2011-03-31 2020-03-02 Univ Iowa Res Found Partícula de AAV2 que comprende una proteína de la cápside de AAV2 y un vector que comprende un ácido nucleico que codifica una tripeptidilo peptidasa 1 (TPP1) para el tratamiento de lipofuscinosis ceroide infantil tardía (LINCL) en un mamífero no roedor mediante inyección intraventricular o administración icv
RU2013150331A (ru) 2011-04-20 2015-05-27 Рош Гликарт Аг СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
SG10201605874TA (en) 2011-04-22 2016-09-29 Genzyme Corp Modified acid alpha glucosidase with accelerated processing
US20120283503A1 (en) 2011-04-29 2012-11-08 The Johns Hopkins University Nanoparticle loaded stem cells and their use in mri guided hyperthermia
DK2714685T3 (en) 2011-05-27 2017-01-09 Ambrx Inc FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
LT2714752T (lt) 2011-05-27 2018-03-12 Amicus Therapeutics, Inc. Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP6166728B2 (ja) 2011-10-14 2017-07-19 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
CA2850373C (fr) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines et conjugues cibles
AU2012322934B2 (en) 2011-10-14 2016-09-08 Medimmune Limited Pyrrolobenzodiazepines
CA2850375C (fr) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines et conjugues cibles
WO2013068874A1 (fr) 2011-11-11 2013-05-16 Pfizer Inc. Conjugués anticorps-médicament
BR112014013526A8 (pt) 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
SMT201900296T1 (it) 2011-12-20 2019-07-11 Regeneron Pharma Topi di catena leggera umanizzata
SG10201704846VA (en) 2012-03-14 2017-07-28 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
EP4124346A3 (fr) 2012-06-19 2023-04-19 University of Florida Research Foundation, Inc. Compositions et procédés de traitement de maladies
HUE051612T2 (hu) 2012-07-11 2021-03-01 Sangamo Therapeutics Inc Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
MX367126B (es) 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
ES2679374T3 (es) 2012-11-27 2018-08-24 Biomarin Pharmaceutical Inc. Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
JP2016514096A (ja) 2013-02-20 2016-05-19 バレリオン セラピューティクス， エルエルシー ポンぺ病の処置のための方法および組成物
WO2014130722A1 (fr) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Méthodes et compositions pour le traitement de la maladie de forbes-cori
EP3964237B1 (fr) 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Molécules biologiquement actives, leurs conjugués, et utilisations thérapeutiques
US10239951B2 (en) 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
US9738717B2 (en) 2013-05-15 2017-08-22 The Translational Genomics Research Institute Hybridoma clones, monoclonal antibodies, and methods of use
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
US9388243B2 (en) 2013-05-29 2016-07-12 Samsung Electronics Co., Ltd. Method of target membrane protein depletion
RU2664471C2 (ru) 2013-07-26 2018-08-17 Юниверсити Оф Айова Рисерч Фаундейшн Способы и композиции для лечения болезней мозга
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
AU2014311361B2 (en) 2013-08-26 2018-11-29 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
AU2015208247B2 (en) 2014-01-21 2021-05-27 Universiteit Gent Muscle-specific nucleic acid regulatory elements and methods and use thereof
KR102496206B1 (ko) 2014-06-11 2023-02-06 몰레큘러 템플레이츠, 인코퍼레이션. 프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
WO2016044947A1 (fr) 2014-09-26 2016-03-31 Exerkine Corporation Exosomes utiles pour traiter une maladie de stockage lysosomal
WO2016065319A1 (fr) 2014-10-24 2016-04-28 Shire Human Genetic Therapies, Inc. Ciblage lysosomal d'enzymes et utilisations associées
CA2967830A1 (fr) 2014-11-14 2016-05-19 Ossianix, Inc. Composes de liaison selectifs de tfr et procedes associes
MA41022A (fr) 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
CA2978340C (fr) 2015-03-27 2024-05-28 Regeneron Pharmaceuticals, Inc. Derives de maytansinoide, conjugues de ceux-ci, et procedes d'utilisation
TWI787796B (zh) 2015-05-04 2022-12-21 美商Ｃｙｔｏｍｘ生物製藥公司 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
CA2990785C (fr) 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. Anticorps anti-recepteur de transferrine humaine passant au travers de la barriere hematoencephalique
JP6993958B2 (ja) 2015-07-06 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性抗原結合分子およびその使用
US10292961B2 (en) 2015-07-15 2019-05-21 Hangzhou Dac Biotech Co., Ltd. Disulfur bridge linkers for conjugation of a cell-binding molecule
AU2016341428B2 (en) 2015-10-23 2021-12-02 University Of Iowa Research Foundation Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection
MY207684A (en) 2015-12-08 2025-03-12 Regeneron Pharma Compositions and methods for internalizing enzymes
IL299470B2 (en) 2015-12-30 2026-05-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
KR20180104148A (ko) * 2016-02-05 2018-09-19 젠맵 에이/에스 개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자
EP3419651B1 (fr) 2016-02-24 2023-10-25 BioMarin Pharmaceutical Inc. Formulation de la protéine de fusion naglu améliorée
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
WO2017190079A1 (fr) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Procédés de production de molécules multispécifiques se liant à l'antigène
WO2017191274A2 (fr) 2016-05-04 2017-11-09 Curevac Ag Arn codant pour une protéine thérapeutique
CA3033082A1 (fr) 2016-08-06 2018-02-15 Ossianix, Inc. Methodes in vivo pour selectionner des peptides qui traversent la barriere hemato-encephalique, compositions apparentees et procedes d'utilisation
KR102617502B1 (ko) 2016-09-12 2023-12-26 제네똥 산-알파 글루코시다제 변이체 및 이의 용도
EP3293203A1 (fr) 2016-09-12 2018-03-14 Genethon Variants d'alpha-glucosidase acide et leurs utilisations
EP3293259A1 (fr) 2016-09-12 2018-03-14 Genethon Variants d'alpha-glucosidase acide et leurs utilisations
US20190269797A1 (en) 2016-11-04 2019-09-05 The Children's Hospital Of Philadelphia Gene transfer compositions, methods and uses for treating neurodegenerative diseases
TWI833178B (zh) 2016-12-26 2024-02-21 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
KR102580320B1 (ko) 2017-01-27 2023-09-19 신텔라 에이비 골 및 연골 손상 또는 질환의 예방 및 치료
CN119113091A (zh) 2017-05-15 2024-12-13 阿米库斯治疗学公司 重组人类酸性α-葡萄糖苷酶
AU2018281280B2 (en) * 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
DK3684423T5 (da) 2017-09-20 2024-08-26 4D Molecular Therapeutics Inc Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
PE20210125A1 (es) 2017-10-14 2021-01-19 Abbvie Inc Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos
CN111683972A (zh) 2018-02-05 2020-09-18 Jcr制药股份有限公司 用于将药剂递送至肌肉的方法
CN111936621B (zh) 2018-02-05 2025-05-13 奥登茨治疗公司 转录调控元件和它的用途
CN112040985A (zh) * 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
JP2021518840A (ja) 2018-03-15 2021-08-05 バレリオン セラピューティクス， エルエルシー ポリグルコサン障害の処置のための方法及び組成物
EP3552631A1 (fr) 2018-04-10 2019-10-16 Inatherys Conjugués d'anticorps-médicament et leurs utilisations pour le traitement du cancer
SG11202011191WA (en) 2018-05-16 2020-12-30 Spark Therapeutics Inc Codon-optimized acid αlpha-glucosidase expression cassettes and methods of using same
EP3793591A1 (fr) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anticorps anti-cd63, conjugués et leurs utilisations
WO2020023390A1 (fr) 2018-07-25 2020-01-30 Modernatx, Inc. Traitement enzymatique substitutif basé sur l'arnm combiné à un chaperon pharmacologique pour le traitement de troubles du stockage lysosomal
EP3830127A4 (fr) 2018-08-02 2022-06-29 Dyne Therapeutics, Inc. Complexes de ciblage musculaire et leurs utilisations pour le traitement de la maladie de pompe
CN113226352B (zh) 2018-08-24 2025-08-26 星火治疗有限公司 最优化启动子序列、无内含子的表达结构及使用方法
WO2020102645A1 (fr) 2018-11-16 2020-05-22 Asklepios Biopharmaceutical, Inc. Virus adéno-associé thérapeutique pour le traitement de la maladie de pompe
BR112021009913A2 (pt) 2018-12-05 2021-08-17 Abeona Therapeutics, Inc. vetor viral adeno-associado recombinante para inserção gênica
WO2020163480A1 (fr) 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Alpha-glucosidase acide humaine recombinée et utilisations associées
US20220193261A1 (en) 2019-04-30 2022-06-23 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of pompe disease
EP3996696A1 (fr) 2019-07-09 2022-05-18 Genethon Traitement de la glycogénose (gsd)
TW202346348A (zh) 2022-01-10 2023-12-01 美商再生元醫藥公司 作為基因治療所遞送之bbb靶向的gaa在龐貝氏症小鼠模型中治療cns及肌肉
IL314482A (en) 2022-02-02 2024-09-01 Regeneron Pharma Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease

Also Published As

Publication number Publication date
PH12020551955A1 (en) 2021-08-16
US12252544B2 (en) 2025-03-18
CA3100021A1 (fr) 2019-11-21
MX2020012350A (es) 2021-01-29
CA3100021C (fr) 2026-03-31
WO2019222663A1 (fr) 2019-11-21
JP7477462B2 (ja) 2024-05-01
AU2019269685B2 (en) 2025-12-04
CL2020002965A1 (es) 2021-08-06
MY206284A (en) 2024-12-06
SG11202011232VA (en) 2020-12-30
CL2024000387A1 (es) 2024-07-05
MX2024014468A (es) 2025-01-09
US20250382377A1 (en) 2025-12-18
CA3290882A1 (en) 2026-03-02
CO2020015052A2 (es) 2020-12-10
EP3793591A1 (fr) 2021-03-24
KR20210010916A (ko) 2021-01-28
CL2022000094A1 (es) 2023-02-24
JP2021524231A (ja) 2021-09-13
KR20250140631A (ko) 2025-09-25
CN112135624B (zh) 2024-07-19
AU2019269685A1 (en) 2020-12-03
US20210079109A1 (en) 2021-03-18
BR112020023145A2 (pt) 2021-02-02
CN112135624A (zh) 2020-12-25
KR102861017B1 (ko) 2025-09-18
AU2026201676A1 (en) 2026-03-26

Similar Documents

Publication Publication Date Title
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3958910A4 (fr) Conjugués anticorps anti-cd45-médicaments et leurs utilisations
EP3794037A4 (fr) Anticorps anti-claudine 18.2 et leurs utilisations
EP3762031A4 (fr) Anticorps anti-claudine 18.2 et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3918323A4 (fr) Anticorps anti-gal3 et leurs utilisations
EP3877416A4 (fr) Anticorps anti-cd45 et leurs conjugués
EP3873512A4 (fr) Anticorps epcam, anticorps activables, et immunoconjugués, et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
EP3411069A4 (fr) Anticorps humanisés anti-cd3, conjugués et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
MA54469A (fr) Anticorps anti-il-27 et leurs utilisations
EP3850012A4 (fr) Anticorps anti-tnfrsf9 et leurs utilisations
EP3962954A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
MA52235A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3755714A4 (fr) Anticorps anti-angiopoïétine-2 et leurs utilisations
EP3562508A4 (fr) Anticorps anti-lair1 et leurs utilisations
EP3672987A4 (fr) Anticorps anti-apéline et leurs utilisations